Do You Know Someone Diagnosed With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)?

Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland are conducting an investigational treatment study with duvelisib to treat patients with ibrutinib-resistant CLL/SLL.

Eligible volunteers must be currently receiving ibrutinib for CLL/SLL and have BTK and/or PLCG2 mutations or progressive CLL/SLL. Compensation for travel may be provided.

Study Design:
- One to two visits to the NIH Clinical Center in Bethesda, Maryland before enrolling in the study followed by clinic visits.
- Clinic visits every 28 days for 6 cycles and every 3 months thereafter.
- Patients will take duvelisib and ibrutinib for 6-months followed by duvelisib alone.
- Treatment and follow up will continue indefinitely until disease progression or if intolerable side effects occur.
- All study-related tests and procedures are provided at no cost.

Who Can Participate?
- Patients 18 years or older diagnosed with CLL/SLL.
- Patients willing to use birth control for the duration of the study.
- Patients willing to participate in all required evaluations and procedures in this study including swallowing capsules without difficulty.

The NIH Clinical Center, America’s research hospital, is in Bethesda, Maryland, on the Metro red line (Medical Center stop).